Download PDF
Semin Thromb Hemost 2007; 33(5): 503-507
DOI: 10.1055/s-2007-982081
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Determination of Antithrombin-Dependent Factor Xa Inhibitors by Prothrombin-Induced Clotting Time

Job Harenberg1 , Christina Giese1 , Antje Hagedorn1 , Inge Traeger1 , Tivadar Fenyvesi1
  • 1Medizinische Klinik, Universitätsklinikum Mannheim, Mannheim, Germany
Further Information

Publication History

Publication Date:
16 July 2007 (online)

    Permissions and Reprints

ABSTRACT

Prothrombinase-induced clotting time (PiCT) determines the anticoagulant effects of heparins, low molecular weight heparins (LMWHs), and direct thrombin inhibitors. At present, this is the only method that measures the effects of all of these inhibitors, in contrast to the prothrombin time, activated partial thromboplastin time (aPTT), Heptest, ecarin clotting time, and the chromogenic assays. The antithrombin-dependent direct factor (F) Xa inhibitors fondaparinux and idraparinux were compared with the LMWH dalteparin on PiCT, aPTT, Heptest, and chromogenic anti-FXa assays in pooled human normal plasma samples. Fondaparinux and idraparinux prolonged the coagulation times in the PiCT, Heptest, and chromogenic FXa assays in a dose-dependent manner, in contrast to the aPTT. We conclude that PiCT is a suitable assay to determine the anticoagulant effects of these two new FXa inhibitors in patients receiving treatment with these compounds.

KEYWORDS

Prothrombinase-induced clotting time - fondaparinux - idraparinux - hirudin - argatroban - and melagatran

REFERENCES

  • 1 Van den Besselaar A M, Meeuwisse-Braun J, Bertina R M. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.  Thromb Haemost. 1990;  63 16-23
    PubMedSearch in Google Scholar
  • 2 Kher A, Gouin I, Samama M M. Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time.  Ann Biol Clin (Paris). 2000;  58 575-579 , [in French]
    PubMedSearch in Google Scholar
  • 3 Kitchen S, Preston F E. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.  Thromb Haemost. 1996;  75 734-739
    PubMedSearch in Google Scholar
  • 4 Hirsh J, Rasdike R. Heparin and low-molecular-weight heparin. The Seventh ACLP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3 suppl) 1885-2035
    PubMedSearch in Google Scholar
  • 5 Harenberg J, Giese Ch, Knödler A, Zimmermann R. Comparative study on a new one-stage clotting assay for heparin and its low-molecular-weight derivates.  Haemostasis. 1989;  19 13-20
    PubMedSearch in Google Scholar
  • 6 Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids.  Semin Thromb Hemost. 1996;  22 197-202
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Calatzis A, Spannagl M, Gempeler-Messina P et al.. The prothrombinase-induced clotting time, a new technique for the monitoring of anticoagulants.  Haemostasis. 2000;  30(suppl 2) 172-174
    CrossrefPubMedSearch in Google Scholar
  • 8 Schöni R. The use of snake-venom derived compounds for new functional diagnostic test kits in the field of haemostasis.  Pathophysiol Haemost Thromb. 2005;  34 234-240
    PubMedSearch in Google Scholar
  • 9 Fenyvesi T, Jörg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method.  Pathophysiol Haemost Thromb. 2002;  32 174-179
    CrossrefPubMedSearch in Google Scholar
  • 10 Hyers T M, Agnelli G, Hull R et al.. Antithrombotic therapy for venous thromboembolic disease.  Chest. 1998;  114(3 suppl) S561-S578
    PubMedSearch in Google Scholar
  • 11 Harenberg J, Schmidt J A, Koppenhagen K, Tolle A, Huismann M V, Büller H R. and the EASTERN Investigators . Fixed-dose, body weight-independent subcutaneous LMW-heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis.  Thromb Haemost. 2000;  83 652-656
    PubMedSearch in Google Scholar
  • 12 The Columbus Investigators . Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med. 1997;  337 657-662
    CrossrefPubMedSearch in Google Scholar
  • 13 Weitz J I. Low molecular weight heparins.  N Engl J Med. 1997;  337 688-698
    CrossrefPubMedSearch in Google Scholar
  • 14 Ginsberg J S. Management of venous thromboembolism.  N Engl J Med. 1996;  335 1816-1828
    CrossrefPubMedSearch in Google Scholar
  • 15 Fenyvesi T, Joerg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors.  Semin Thromb Hemost. 2002;  28 361-368
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Graff J, Picard-Willems B, Harder S. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.  Int J Clin Pharmacol Ther. 2007;  45 237-243
    PubMedSearch in Google Scholar

Prof. Dr. med. J Harenberg

IV, Medizinische Klinik, Universitätsklinikum Mannheim

Theodor-Kutzer-Ufer, D-68167 Mannheim, Germany

Email: job.harenberg@med.ma.uni-heidelberg.de